Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
|
| |||
Ablynx NV* |
Kirin Brewery Co. Ltd. (Japan) |
Collaboration focused on the use of Nanobodies as therapeutic products |
Specifics on the research and license agreement were not disclosed (2/9) |
Ablynx NV* |
Novartis AG (Switzerland) |
Deal to to discover and develop Nanobody-based drugs against a number of targets in a range of diseases |
Ablynx gets up-front fees, license fees and R&D funding and is eligible to receive milestone and royalty payments (1/18) |
Ablynx NV* |
Centocor Inc. (unit of Johnson & Johnson) |
Deal to jointly work on approaches for administration and delivery of Nanobody-based therapeutics |
Centocor will fund the research; further terms were not disclosed (1/11) |
ActiveSight |
Novo Nordisk A/S (Denmark) |
ActiveSight will provide protein crystallography services for Novo |
ActiveSight will co-crystallize Novo molecules with proteins expressed by ActiveSight; terms were not disclosed (1/23) |
Affymax Inc.* |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Takeda got rights to develop and sell Affymax's anemia product Hematide in Japan |
Affymax gets a $17M up-front payment and a $10M equity investment; it also could get clinical and regulatory milestones of $75M, and double-digit royalties on sales (2/13) |
Alkermes Inc. |
Eli Lilly and Co. |
Deal to develop inhaled formulations of parathyroid hormone using Alkermes' AIR pulmonary delivery system |
Alkermes gets up-front, development and potential milestone payments, as well as royalties on any sales; Lilly's PTH product Forteo was approved in 2002 (1/9) |
Alnylam |
Novartis AG (Switzerland) |
They formed a collaboration to develop RNAi therapeutics for pandemic flu |
The deal is in addition to a broad collaboration they signed in September 2005; terms were not disclosed (2/21) |
Alnylam |
Dharmacon Inc. (unit of Fisher Biosciences) |
Dharmacon got nonexclusive rights to provide RNAi research products and services under Kreutzer-Limmer patents |
The patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (1/5) |
AlphaVax Inc.* |
Wyeth |
New deal gives Wyeth exclusive access to all relevant AlphaVax technologies for certain infectious diseases |
The enhancement of their 1998 deal refocuses the disease targets and adds exclusivity; AlphaVax gets an equity investment and is entitled to significantly more funding than in the original deal (1/12) |
Amira |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Amira will optimize compounds against inflammatory disease targets; separately, Amira got an option to license two clinical-stage Roche compounds |
Under the research deal, Roche would have opt-in rights on two programs, for which it could pay Amira up to $287M, plus royal- ties; in the license deal, Amira has a one- year option to the Roche programs in certain indications; Roche could get significant Almira equity, $20M in milestones and royalties on sales (1/9) |
Aphton Corp. |
BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan) |
Apthon subsidiary Igeneon got nonexclusive rights to use BioWa's Potelligent technology |
Igeneon will use the technology in development of a next-generation Lewis Y-specific antibody, IGN312; terms of the deal were not disclosed (2/14) |
Argenta |
Dr. Reddy's Laboratories (India) |
Deal to jointly develop clinical candidates from a class of Dr. Reddy compounds for treating chronic obstructive pulmonary disease |
They will fund development through Phase IIa trials, then continue development or license out candidates; terms of the deal were not disclosed (2/2) |
Asterand plc |
BTG plc (UK) |
BTG got rights to a series of preclinical compounds for treating pain and related conditions |
Asterand gets an undisclosed up-front payment and could earn milestone and royalty payments in the deal (1/30) |
Astex |
Pfizer Inc. |
Pfizer got nonexclusive rights to use Cytochrome P450 crystal structure data |
Astex gets an up-front fee in the deal; further terms were not disclosed (1/24) |
Athersys Inc.* |
Bristol-Myers Squibb Co. |
They extended deal under which Athersys is applying its RAGE technology to provide drug targets to BMS |
Athersys is entitled to license fees for targets delivered to BMS, as well as potential milestone and royalty payments on resulting compounds (1/6) |
AVEO |
Mitsubishi Pharma Corp. (Japan) |
AVEO acquired rights outside Asia to Mitsubishi's kinase inhibitor MP-412 |
AVEO intends to start clinical studies by mid-2006; the initial focus is solid tumors; terms of the deal were not disclosed (1/5) |
Avigen Inc. |
SDI Diagnostics International Ltd. (unit of Sanochemia Pharmazeutika AG; Austria) |
Avigen got North American rights to formulations of tolperisone (AV650), a small molecule for treating neuromuscular conditions |
SDI gets $3M up front and is eligible to receive milestone and royalty payments; the product is approved in Europe; SDI also will manufacture the product (1/16) |
Axonyx Inc. |
Daewoong Pharmaceutical Co. Ltd. (South Korea) |
Daewoong got rights to sell the Alzheimer's drug candidate Phenserine in South Korean |
Axonyx is entitled to royalty payments; Daewoong is responsible for development in South Korea; further terms were not disclosed (1/4) |
BioCryst |
Mundipharma International Holdings Ltd. (UK) |
Mundipharma got rights to Fodosine in oncology fields, in Europe, Asia and Australia |
BioCryst gets $10M up front and up to $155M in milestone payments, as well as royalties on sales; Mundipharma also will pay up to $25M in development costs (2/2) |
BioSphings |
Shogoo Pharmaceuticals KK (Japan) |
Shogoo got worldwide rights to BioSphings' SPK-0601, a small molecule that acts on viral gene expression |
BioSphings gets an up-front payment as well as potential milestone and royalty payments (2/2) |
Biovitrum AB* |
Helsinn Healthcare SA (Switzerland) |
Biovitrum got exclusive rights to the antiemetic drug Aloxi in the Nordic region |
The product already is on the market in parts of Europe; terms of the deal were not disclosed (2/16) |
Cadence |
Bristol-Myers Squibb Co. |
Cadence acquired rights in the U.S. and Canada to an intravenous formulation of acetaminophen |
BMS gets an up-front payment and could receive milestone and royalty payments in the deal (2/22) |
Caprion |
Berlex Inc. (unit of Schering AG; Germany) |
Collaboration using Caprion's CellCarta proteomics platform for biomarker discovery |
Caprion will identify biomarkers in plasma resulting from administration of preclinical Berlex compounds; terms were not disclosed (1/24) |
Cara |
ALZA Corp. (unit of Johnson & Johnson) |
ALZA got rights to Cara's peripherally acting pain drug candidate CR665, which has completed a Phase Ia trial |
Cara gets an up-front payment and could receive milestone payments and royalties on sales; it also retained a U.S. co-promotion option on intravenous products (1/5) |
Celera |
Applied Biosystems Group |
Celera acquired ABG's 50% interest in their Celera Diagnostics joint venture |
Both Celera and ABG are units of Applera Corp.; terms of the restructuring were not disclosed (1/9) |
Cell Signaling |
AstraZeneca plc (UK) |
CST's PhosphoScan technology will be used on research on kinase-targeted compounds |
The technology enables discovery of drug target phospho-profiles in cells and disease tissue; terms were not disclosed (1/10) |
Cephalon Inc. |
Mylan Laboratories Inc. |
Deal to use Mylan's transdermal technology to develop products for pain and central nervous system disorders |
Mylan is entitled to milestone and royalty payments in the deal; further terms were not disclosed (1/11) |
Cerimon |
Novartis Pharma AG (Switzerland) |
Cerimon acquired worldwide rights to Simulect (basiliximab) for treating inflammatory bowel disease |
Novartis already markets the antibody for preventing organ rejection in renal transplant recipients; Cerimon is eligible for milestone payments in the deal, and Novartis would get a share of revenues on sales for IBD (2/21) |
ChemGenex |
Merck KGaA (Germany) |
ChemGenex will provide preclinical support in the areas of diabetes, insulin resistance and complications |
Payments under the three-year deal will depend on the amount and type of support provided; the deal followed target discovery work between the companies (1/16) |
Chromos |
Pfizer Inc. |
Expanded deal under which Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein |
They also will collaborate to genetically engineer production cell lines; Pfizer will fund the new programs (1/9) |
Ciphergen |
Sanofi-Aventis Group(France) |
Deal to discover biomarkers for a preclinical study in the field of oncology |
Ciphergen will use its proteomics technologies in the effort; terms of the deal were not disclosed (2/7) |
Codexis Inc.* |
Bristol-Myers Squibb Co. |
They extended deal focused on improving the biocatalyst productivity of a BMS product |
Codexis gets additional research funding under the extension of the May 2005 deal; terms were not disclosed (1/31) |
Cue Biotech |
H. Lundbeck A/S (Denmark) |
Deal to discover and develop drugs for central nervous system diseases and disorders |
The focus is on small molecules targeting G protein- coupled receptors; terms of the deal were not disclosed (1/24) |
CytoGenix |
Fast Trak BioDefense (unit of GE Healthcare) |
Collaboration to obtain biodefense-related federal contracts |
Contract calls for them to compete for federal research projects; terms were not disclosed (12/27) |
Diversa Corp. |
BASF (Germany) |
Broad agreement to develop products for industrial applications |
The deal expands a relationship between them from 2001 for developing biocatalysts; terms were not disclosed (2/16) |
Emisphere |
Novartis AG (Switzerland) |
A court said Emisphere's deal with Lilly on oral parathyroid hormone was properly terminated as of August 2004 |
The ruling allows Emisphere to now license its eligen technology for use with PTH to Novartis for treatment of osteoporosis; Emisphere is entitled to milestone and royalty payments (1/9) |
Endocyte Inc.* |
Bristol-Myers |
BMS got rights to Endocyte's vitamin-targeting technology for targeting epothilone cancer chemotherapeutic agents |
The deal follows an ongoing collaboration; Endocyte gets a $3M license payment and potential milestone and royalty payments (1/5) |
EntreMed |
Elan Corp. plc (Ireland) |
EntreMed got rights to use Elan's NanoCrystal technology to develop the cancer product candidate Panzem NCD |
Elan is eligible to receive milestone and royalty payments in the deal; also, Elan will manufacture Panzem NCD, a NanoCrystal technology formulation of the drug (1/10) |
Epitome |
Bristol-Myers Squibb Co. |
Epitome will develop biomarker assay panels for BMS |
Epitome will use its EpiTag protein measurement platform in the deal; it is entitled to development funding and license fees (1/4) |
EPIX |
Schering AG (Germany) |
Schering exercised its option to develop a gadofluorine derivative discovered in their collaboration |
The product is intended for the diagnosis of atherosclerosis and other vascular diseases; EPIX would get royalties on any resulting sales (2/10) |
Evotec AG |
Cellomics Inc. (unit of Fisher Biosciences) |
Evotec Technologies GmbH got rights to Cellomics' High Content Screening technology |
The companies also are collaborating to develop and market combined offerings in cell biology solutions; terms were not disclosed (1/30) |
Evotec AG |
Boehringer Ingelheim started in September 2004 |
They expanded and extended drug discovery collaboration research support, along with potential |
The focus was extended from GPCR targets to other classes; Evotec gets ongoing FSE:EVT) milestone and royalty payments (1/17) |
Evotec AG |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Evotec got rights to two monoamine oxidase-B inhibitors that are in Phase I trials for Alzheimer's disease |
Roche gets an up-front fee and potential milestone and royalty payments; it also retained a late-stage co- development option; Roche would get Evotec stock upon initiation of Phase II trials (1/9) |
Galapagos NV |
BASF (Germany) |
They extended three research collaborations into 2006; Galapagos division BioFocus is providing the services |
BASF will pay compound supply and access fees in the contract extensions, which are valued at more than €700,000 (2/2) |
Galapagos NV |
Boehringer Ingelheim GmbH (Germany) |
Three-year deal in field of autoimmune discovery research; Galapagos division BioFocus will do the work |
Galapagos gets up-front fees, R&D funding and could receive milestone fees, which together could exceed €2M (1/16) |
GeneGo Inc.* |
Merck & Co. Inc. |
Merck extended for two years its right to use GeneGo technologies |
Merck is using the MetaCore and MetaBase technologies in R&D programs; terms of the deal were not disclosed (1/9) |
G2 Therapies |
Novo Nordisk A/S (Denmark) |
Deal to develop and market anti-inflammatory drugs based on G2's C5a receptor antibodies |
G2 gets $6M up front and up to $96M in milestone payments, as well as royalties on resulting sales; it also gets expense reimbursement (2/8) |
Hybrigenics |
Theramex (affiliate of Merck KGaA; Germany) |
Hybrigenics got worldwide rights to inecalcitol, a synthetic vitamin D analogue |
Hybrigenics intends to develop products for cancer and partner the drug in other indications; terms of the deal were not disclosed (2/7) |
IDM Pharma |
Genesis Pharma (Greece) |
Genesis got rights in southeast Europe to the immune system stimulator Junovan |
The product has completed a Phase III trial in osteosarcoma; IDM is entitled to an upfront license fee and sales-based milestone payments (2/21) |
ImQuest |
Samjin Pharmaceutical Co. Ltd. (South Korea) |
Deal under which ImQuest will provide preclinical and clinical development support |
ImQuest will work on small molecules provided by Samjin; terms of the deal were not disclosed (1/24) |
Innovive |
Nippon Shinyaku Co. Ltd. (Japan) |
Innovive got all rights outside Japan to NS-187, an inhibitor of Bcr-Abl and Lyn kinase |
Innovive will develop the product for chronic myelogenous leukemia; Phase I trials are expected in 2006; terms of the deal were not disclosed (1/5) |
Inspire |
Boehringer Ingelheim International GmbH (Germany) |
Inspire acquired rights to develop and market an intra- nasal form of epinastine in the U.S. and Canada for treating or preventing rhinitis |
BI gets an up-front license fee and would get single-digit royalties on resulting sales; it also retained rights outside the U.S. and Canada; Inspire will fund development (2/21) |
KAI |
Sankyo Co. Ltd. (subsidiary of Daiichi Sankyo Co. Ltd; Japan) |
Collaboration to develop drugs for cardiovascular disease; the initial focus is on the Phase I/II delta protein kinase C inhibitor KAI-9803 |
KAI gets $20M up front and could get mile- stones of up to $300M for two indications for KAI-9803, as well as milestone payments for future delta PKC inhibitors; Sankyo gets global rights, will fund all development and would pay double-digit royalties on sales (1/9) |
Kalypsys Inc.* |
Alcon Inc. |
Kalypsys will use its technologies for the discovery of ophthalmic drug candidates under a four-year deal |
Kalypsys gets an access fee, research support and potential milestone payments, as well as royalties on any sales; Alcon also got preferred partnering access to compounds from Kalypsys programs (1/4) |
Keryx Bio- |
Panion & BF Biotech Inc. (Taiwan) |
Keryx gained rights outside Asia to Zerenex, an oral iron-based compound |
Panion is entitled to up-front, milestone and royalty payments on the drug, which is in Phase II clinical development for treating hyperphosphatemia (2/15) |
LibraGen* |
Pierre Fabre Medicament (France) |
LibraGen will optimize the synthesis of a Pierre Fabre molecule |
LibraGen will use its enzymatic technologies in the deal, terms of which were not disclosed (1/5) |
Locus |
Eli Lilly and Co. |
Locus will use its computational technologies to design small- olecule compounds for Lilly |
The focus is a protein kinase target identified by Lilly; terms of the deal were not disclosed (1/31) |
Medarex |
Organon NV (the Netherlands) |
Organon got rights to use Medarex's UltiMAb technology for antibody discovery and development |
Medarex is entitled to license fees, milestone payments and royalties on any resulting sales (2/1) |
MerLion |
Novartis Institute for Tropical Diseases (Singapore) |
Collaboration initially focused on discovering compounds for treating Dengue fever |
MerLion will screen its natural compounds against an NITD target; Novartis has an option to license resulting candidates, and also can license compounds for different indications (1/19) |
Micromet AG* |
Undisclosed pharmaceutical company |
The unnamed company got rights to develop and sell a single-chain antibody product for treating cancer |
The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18) |
Micromet AG* |
Abbott Laboratories |
Abbott gained a research license to single-chain antibody technology |
The deal was made under Micromet's marketing deal with Enzon Pharmaceuticals Inc., which will get a share of any proceeds (1/18) |
Monogram |
Merck & Co. Inc. |
Monogram will apply its testing technologies for use in Phase III trials of MK-0518, Merck's HIV-1 integrase inhibitor |
The PhenoSense and GeneSeq technologies will be used for HIV phenotypic and genotypic testing; terms of the deal were not disclosed (2/21) |
Nastech |
Procter & Gamble Pharmaceuticals Inc. |
P&G got worldwide rights to Nastech's PTH1-34, a para- thyroid hormone nasal spray for treating osteoporosis |
Nastech gets $10M up front and milestone payments up to $22M in the first year; total payments could reach $577M if all goals are reached; Nastech also would get double-digit royalties on sales (2/1) |
Novosom |
Boehringer Ingelheim Pharma GmbH (Germany) |
Collaboration to validate liver and pulmonary targets in vivo using siRNA technology from Novosom |
BI will fund the program; further terms were not disclosed (1/16) |
NPS |
AstraZeneca plc (UK) |
They extended for at least three years a deal to discover and develop drugs targeting metabotropic glutamate receptors |
AstraZeneca already is in Phase I trials with a collaboration candidate; the focus is on treating central nervous system and gastrointestinal disorders; terms were not disclosed (2/8) |
Nuvelo Inc. |
Bayer HealthCare AG (Germany) |
Bayer got rights outside the U.S. to Nuvelo's Phase III thrombolytic drug alfimeprase; Nuvelo retained all U.S. rights |
Nuvelo gets $50M up front, up to $165M in development milestones and up to $170M in sales milestones, as well as royalties up to 37.5%; Bayer also will pay 40% of development costs (1/5) |
Ocera |
Kureha Corp. (Japan) |
Ocera got rights to AST-120 in Europe and North America |
Ocera is planning to start trials of the product, which is targeted at liver and gastro- intestinal diseases; the initial indication is Crohn's disease (1/17) |
Opsona |
Wyeth Pharmaceuticals |
Deal to discover and market compounds to treat inflammatory diseases, based on Toll-like receptor targets |
Opsona gets an up-front payment and R&D funding, as well as potential milestone and royalty payments; it also has an option to develop resulting drugs in topical indications (2/13) |
Oscient |
Pfizer SA de CV (Mexico) |
Pfizer got rights to the antibiotic product Factive in Mexico |
Oscient gets an up-front payment, as well as potential regulatory and sales milestones and royalties on sales (2/7) |
PerlegenSciences Inc.* |
Pfizer Inc. |
Four-year deal for whole- genome and replication studies to identify genes associated with diseases and to predict patient responses to certain drugs |
Perlegen gets research payments; the companies will share in certain resulting intellectual property rights; the deal followed by one day a $50M equity investment in Perlegen by Pfizer; they have been partners since 2002 (12/28) |
Primagen |
BioMerieux SA (France) |
BioMerieux got rights to a newly discovered coronavirus implicated in respiratory diseases |
BioMerieux plans to develop a test for the virus, CoV-NL63; it also has sublicensing rights; terms were not disclosed (2/1) |
Progenics |
Wyeth |
Deal to develop and market Progenics' Phase III product methylnaltrexone (MNTX) for treating opioid-induced side effects |
Progenics gets $60M up front and up to $356.5M in milestone payments, as well as royalties on any sales; Progenics also retained a U.S. co-promotion option(12/23) |
PDL BioPharma |
Merck & Co. Inc. |
Merck got nonexclusive rights under PDL's humanization patents to develop antibodies against two antigens |
PDL is entitled to an up-front licensing payment, development milestones and royalties on any sales; the antigens were not disclosed (12/3) |
Replidyne Inc.* |
Forest Laboratories Inc. |
Deal for the commercialization of Replidyne's oral antibiotic faropenem medoxomil in the U.S.; an NDA was filed in January |
Replidyne gets $50M up front and potential milestone payments; it also would get royalties on sales; Replidyne retained certain marketing rights (2/13) |
Sangamo |
Pfizer Inc. |
New deal expands the scope of existing collaboration in the field of enhanced protein production |
Pfizer will fund further research at Sangamo, which will use its zinc finger DNA-binding protein technology to develop additional cell lines (1/4) |
Sareum |
UCB Pharma (Belgium) |
Sareum will provide protein structure determination capabilities to accelerate UCB research in cancer |
Sareum is entitled to access fees and milestone payments in the deal; further terms were not disclosed (1/26) |
Sareum |
H. Lundbeck A/S (Denmark) |
Sareum will provide protein structure determination capabilities to accelerate discovery research at Lundbeck |
Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/19) |
Sareum |
Organon NV (the Netherlands) |
Sareum will generate lead chemical series against two Organon autoimmune disease protein targets |
Sareum is entitled to research fees and milestone payments in the deal; specific terms were not disclosed (1/17) |
Scottish |
Chong Kun Dang (South Korea) |
Collaboration on development of a drug for diabetes |
Scottish Biomedical will provide chemistry and biology services on small molecules believed to be active against a diabetes target; terms were not disclosed (1/31) |
Senexis Ltd.* |
BTG plc (UK) |
Senexis got rights to inhibitors of amyloid-induced toxicity and neuroinflammation |
BTG is entitled to milestone and royalty payments in the deal (2/2) |
Shanghai |
Organon NV |
Collaboration to advance Organon's program for identifying more-selective steroid hormone receptor modulators |
The deal, initially for two years, will focus on the areas of rheumatoid arthritis, atherosclerosis and oncology; terms were not disclosed (1/24) |
Targacept |
AstraZeneca plc (UK) |
Deal to develop and market Targacept's Phase II drug TC- 734 for Alzheimer's disease and other cognitive disorders |
Targacept gets $10M up front, $26M in research funding and would get $20M if AstraZeneca starts a Phase II program; Targacept also could earn about $244M in milestone payments and double-digit royalties on sales (12/28) |
Tripos Inc. |
Wyeth Pharmaceuticals |
Wyeth will use Tripos' discovery informatics technology as the basis for its information technology solution |
Tripos expects to receive about $5M in software license and service fees over 12 to 18 months, with certain payments contingent on milestone achievements (1/11) |
Trubion |
Wyeth Pharmaceuticals |
Deal to develop and sell drugs for inflammatory diseases and cancer based on Trubion's Small Modular Immuno-pharmaceutical technology |
Trubion gets $40M up front and up to $760M in milestone payments, as well as royalties on sales; Trubion retains an option to co-promote CD20- targeted therapies in the U.S. for certain indications; Wyeth also would invest in Trubion if it conducts an initial public offering (1/3) |
Vaccinex Inc.* |
Schering AG (Germany) |
Deal to identify disease targets and potentially develop drugs for treating certain cancers |
Vaccinex gets a technology access fee and research funding and is eligible for milestone and royalty payments; its also has certain co-development options (2/10) |
VaxGen Inc. |
Becton, Dickinson and Co. |
Deal to evaluate BD's Micro Injection technology to deliver VaxGen's recombinant anthrax vaccine candidate |
The collaboration will include a Phase I trial of the dermal injection; the work is being funded through a contract between BD and the Department of Defense (2/21) |
Xencor Inc.* |
Centocor Inc. (unit of Johnson & Johnson) |
Centocor got nonexclusive rights to use ImmunoFilter technology to evaluate the immunogenicity of its proteins |
Xencor gets annual license fees under the multiyear deal; further terms were not disclosed (2/14) |
Xencor Inc.* |
Eli Lilly and Co. |
Lilly got nonexclusive rights to use Xencor's ImmunoFilter technology to evaluate the immunogenicity of its proteins |
Terms of the multiyear licensing deal were not disclosed (1/18) |
Xencor Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
They extended deal to create monoclonal antibodies with differentiated pharmacological profiles |
Roche is applying Xencor's XmAb Fc domains to enhance the efficacy of an antibody against a cancer target; Xencor gets additional fees under the extension and remains entitled to milestone and royalty payments (1/4) |
YM BioSciences |
Sanofi-Aventis Group (France) |
Deal to investigate the combination of tesmilifene and docetaxel for treating metastatic breast cancer |
The initial trial will enroll up to 39 patients; prior Phase III data on the combination showed increased survival; terms were not disclosed (1/10) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSE = Toronto Stock Exchange. | |||
